Analytics

Kenji Tabata, PhD, is senior vice-president, head of Discovery Intelligence, Applied Research & Operations, at Japan-based pharmaceutical company Astellas.

Articles

Advancing digital transformation can significantly reduce R&D costs and shorten drug discovery timelines.

Digital Transformation: Accelerating Small-Molecule Drug Discovery

Feliza Mirasol is the science editor for 

Although well known in R&D, PK/PD studies are an equally powerful tool for promoting successful biologic drug development.

The Power of PK/PD in mAb Development

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Dissolution testing is experiencing a refresh thanks to a variety of market drivers.

Building Up to a Bright Future

Biotech startup, Cradle, has raised $5.4 million in seed funding with an AI-enabled design platform that allows for the synthetic building of cell factories to produce proteins.

Biotech Startup Raises $5.4M to Develop AI-Designed Protein Machines and Cell Factories

Wai-Chi Man is IC/SP product marketing manager at Thermo Fisher Scientific.

Replacing a step in sample preparation with an automated approach improves both method precision and productivity.

Automating a Critical Step in Glycoprotein Analysis for Vaccine Manufacture

Meg Rivers is the former senior editor for 

Experts discuss factors that can affect the outcome of an ADME study, signs that a drug compound shows promise, red flags, and key parameters to determine safety and efficacy. 

ADME Studies: Determining Promising Drug Compounds 

Jennifer Markarian is a contributing editor for 

Single-use systems can benefit from standardized risk assessment and analysis protocols, which can facilitate the way in which processing equipment components are compared.

Considerations for E&L Analysis in Single-Use Systems

Klaus Lindpaintner, MD, MPH is chief scientific officer and distinguished scientist at InterVenn BioSciences.

With the evolution of scalability of peripheral blood protein glycosylation, research has expanded for new biomarkers.

Using Novel Biomarkers to Facilitate AI-Driven Glycoproteomics

An early drug candidate screening strategy should incorporate clear targets to lessen late-stage failure.

Using a Drug Candidate Screening Strategy to Mitigate Late-Stage Risk

Pramote Cholayudth previously was the managing director of the Professional Conference Center, Ltd. He currently is a validation consultant to Biolab Co., Ltd., in Thailand. He is the founder and manager of PM consult, cpramote2000@yahoo.com.

This article introduces a control chart technique using F statistic for continued process verification of oral solid dosage forms.

Analytical Method Development